Proteasome inhibition promotes regression of left ventricular hypertrophy - PubMed (original) (raw)
. 2008 Feb;294(2):H645-50.
doi: 10.1152/ajpheart.00196.2007. Epub 2007 Nov 21.
Affiliations
- PMID: 18032525
- DOI: 10.1152/ajpheart.00196.2007
Free article
Proteasome inhibition promotes regression of left ventricular hypertrophy
William E Stansfield et al. Am J Physiol Heart Circ Physiol. 2008 Feb.
Free article
Abstract
Current research in left ventricular hypertrophy (LVH) has largely focused on its progression and therapeutic mechanisms to prevent or slow its development. Few studies have centered on the regression or treatment of existing LVH. Nuclear factor-kappaB (NF-kappaB) is an inflammatory transcription factor that has been shown to be involved in LVH development. We hypothesized that proteasome-mediated NF-kappaB inhibition would prevent the development of LVH and promote its regression. A murine model of reversible hypertrophy was employed by administering isoproterenol (Iso) subcutaneously for 7-14 days. The proteasome inhibitor, PS-519, was delivered both concurrently and after Iso treatment. LVH was quantified by heart weight-to-body weight ratios, histology, transthoracic echocardiography, and hypertrophic gene expression. After 7 days of Iso treatment, all measures indicated successful development of LVH. Another group was treated for 7 days and then observed for an additional 7 days. This group experienced normalization of Iso-induced cell size, wall thickness, and beta-myosin heavy chain expression. When administered concurrently, PS-519 prevented Iso-induced LVH at 7 days. Furthermore, when PS-519 was given to animals during the second week of continued Iso treatment, these animals also experienced regression of hypertrophy by several measures. The success of proteasome inhibition in preventing LVH development and in promoting LVH regression, even in the face of continued hypertrophic stimulation, demonstrates its potential use as a clinically accessible strategy for treating patients with a variety of LVH-associated cardiomyopathies.
Similar articles
- Inhibitory kappa-B kinase-β inhibition prevents adaptive left ventricular hypertrophy.
Andersen NM, Tang R, Li L, Javan H, Zhang XQ, Selzman CH. Andersen NM, et al. J Surg Res. 2012 Nov;178(1):105-9. doi: 10.1016/j.jss.2012.03.003. Epub 2012 Mar 22. J Surg Res. 2012. PMID: 22464396 Free PMC article. - Vitamin D attenuates pro-inflammatory TNF-α cytokine expression by inhibiting NF-кB/p65 signaling in hypertrophied rat hearts.
Al-Rasheed NM, Al-Rasheed NM, Bassiouni YA, Hasan IH, Al-Amin MA, Al-Ajmi HN, Mohamad RA. Al-Rasheed NM, et al. J Physiol Biochem. 2015 Jun;71(2):289-99. doi: 10.1007/s13105-015-0412-1. Epub 2015 May 1. J Physiol Biochem. 2015. PMID: 25929726 - Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction.
Woodiwiss AJ, Tsotetsi OJ, Sprott S, Lancaster EJ, Mela T, Chung ES, Meyer TE, Norton GR. Woodiwiss AJ, et al. Circulation. 2001 Jan 2;103(1):155-60. doi: 10.1161/01.cir.103.1.155. Circulation. 2001. PMID: 11136701 - Echocardiographic quantification of left ventricular mass: prognostic implications.
Swamy RS, Lang RM. Swamy RS, et al. Curr Cardiol Rep. 2010 May;12(3):277-82. doi: 10.1007/s11886-010-0104-y. Curr Cardiol Rep. 2010. PMID: 20424973 Review. - Regression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patients.
Verdecchia P, Angeli F, Pittavini L, Gattobigio R, Benemio G, Porcellati C. Verdecchia P, et al. Ital Heart J. 2004 Jul;5(7):505-10. Ital Heart J. 2004. PMID: 15487267 Review.
Cited by
- Genetic ablation of Lmp2 increases the susceptibility for impaired cardiac function.
Trogisch FA, Koser F, Michel S, Liem DA, Florea BI, Hecker M, Drews O. Trogisch FA, et al. Front Mol Biosci. 2024 Mar 7;11:1148948. doi: 10.3389/fmolb.2024.1148948. eCollection 2024. Front Mol Biosci. 2024. PMID: 38516190 Free PMC article. - Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review.
Georgiopoulos G, Makris N, Laina A, Theodorakakou F, Briasoulis A, Trougakos IP, Dimopoulos MA, Kastritis E, Stamatelopoulos K. Georgiopoulos G, et al. JACC CardioOncol. 2023 Feb 21;5(1):1-21. doi: 10.1016/j.jaccao.2022.12.005. eCollection 2023 Feb. JACC CardioOncol. 2023. PMID: 36875897 Free PMC article. Review. - Calpains as Potential Therapeutic Targets for Myocardial Hypertrophy.
Aluja D, Delgado-Tomás S, Ruiz-Meana M, Barrabés JA, Inserte J. Aluja D, et al. Int J Mol Sci. 2022 Apr 7;23(8):4103. doi: 10.3390/ijms23084103. Int J Mol Sci. 2022. PMID: 35456920 Free PMC article. Review. - Induction of Proteasome Subunit Low Molecular Weight Protein (LMP)-2 Is Required to Induce Active Remodeling in Adult Rat Ventricular Cardiomyocytes.
Petersen A, Kutsche HS, Nippert F, Schreckenberg R, Schulz R, Schlüter KD. Petersen A, et al. Med Sci (Basel). 2020 May 1;8(2):21. doi: 10.3390/medsci8020021. Med Sci (Basel). 2020. PMID: 32370048 Free PMC article. - Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management.
Patel VG, Cornell RF. Patel VG, et al. Curr Oncol Rep. 2019 Mar 5;21(4):29. doi: 10.1007/s11912-019-0784-4. Curr Oncol Rep. 2019. PMID: 30834998 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources